Most of the real safety risk comes from unregulated, gray-market products not from properly prescribed ones
Physiol Plant 173(4):19791991
(PubMed) Trupp RJ, Abraham WT
doi: 10.3390/DIAGNOSTICS13203227 158 NicholsonWKSilversteinMWongJBBarryMJChelmowDCokerTRet al
References Rosamond W, Flagel K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinburger J, Thom T, Wasserthiel-Smoller S, Hong Y, American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
If you need a concrete product example, Peptide Warehouse USA lists a CJC-1295 (NO-DAC) + Ipamorelin Blend for research catalog purposes, which is relevant when protocol design involves combined peptide systems rather than ipamorelin alone
